Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles Sells 32,393 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 32,393 shares of Alphatec stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $10.89, for a total transaction of $352,759.77. Following the transaction, the chief executive officer now directly owns 5,940,391 shares in the company, valued at $64,690,857.99. This trade represents a 0.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Wednesday, February 5th, Patrick Miles sold 43,459 shares of Alphatec stock. The stock was sold at an average price of $11.95, for a total transaction of $519,335.05.
• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The shares were sold at an average price of $12.03, for a total value of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Price Performance

Shares of NASDAQ ATEC opened at $11.06 on Thursday. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $15.41. The stock has a market capitalization of $1.57 billion, a P/E ratio of -8.64 and a beta of 1.43. The company’s 50-day moving average is $10.57 and its 200 day moving average is $8.35. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, sell-side analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Alphatec

Institutional investors have recently added to or reduced their stakes in the company. Lido Advisors LLC grew its position in shares of Alphatec by 8.4% in the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after buying an additional 953 shares during the period. PNC Financial Services Group Inc. boosted its stake in Alphatec by 0.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after acquiring an additional 1,120 shares in the last quarter. Comerica Bank grew its holdings in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares during the period. Summit Investment Advisors Inc. grew its holdings in Alphatec by 14.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock worth $100,000 after purchasing an additional 1,342 shares during the period. Finally, Atria Investments Inc increased its stake in shares of Alphatec by 8.0% during the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after purchasing an additional 1,460 shares in the last quarter. Institutional investors own 66.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ATEC. Needham & Company LLC lifted their price target on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Finally, Barclays increased their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.